Seetharamaiyer Padmanabhan

This inventor holds 16 USPTO granted patents and 7 published patent applications and 2 EPO patents. Top assignees: Spring Bank Pharmaceuticals, Inc., F-Star Therapeutics, Inc., Invox Pharma Limited. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Seetharamaiyer Padmanabhan. Retrieved from https://idiyas.com/inventor/seetharamaiyer-padmanabhan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 7)

% Patents Active = 56.3

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 2.7

ph-index = 4

Forward Citations = 86(Granted Patents)

Location History:

Malden, MA (US) (2006)
Lexington, MA (US) (2004 - 2023)

Company Filing History:

8 out of 9

Spring Bank Pharmaceuticals, Inc.

patents

2 out of 11

F-Star Therapeutics, Inc.

Cambridge Neuroscience, Inc.

patents

5. 1 out of 4

Scion Pharmaceuticals, Inc.

patents

6. 1 out of 2

Sperovie Biosciences, Inc.

Years Active: 2004-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12667573 - Compounds, compositions, and methods for the treatment of disease (2026-06-30),

2. 12187761 - Compounds, compositions, and methods for the treatment of disease (2025-01-07),

3. 11744845 - Compounds,compositions, and methods for the treatment of disease (2023-09-05),

4. 11584774 - Compounds, compositions, and methods for the treatment of disease (2023-02-21),

5. 11033569 - Compounds,Compositions, and methods for the treatment of disease (2021-06-15),

6. 10376533 - Compositions and methods for treating viral infections (2019-08-13),

7. 10344046 - Nucleotide and oligonucleotide prodrugs (2019-07-09),

8. 10047114 - Nucleotide and oligonucleotide prodrugs (2018-08-14),

9. 9539276 - Compositions and methods for treating viral infections (2017-01-10),

10. 9138442 - Compositions and methods for treating viral infections (2015-09-22),

11. 8691787 - Nucleotide and oligonucleotide prodrugs (2014-04-08),

12. 8404651 - Compositions and methods for treating viral infections (2013-03-26),

13. 8287700 - Methods and processes for attaching compounds to matrices (2012-10-16),

14. 8076303 - Nucleotide and oligonucleotide prodrugs (2011-12-13),

15. 7041702 - Pharmaceutically active compounds and methods of use (2006-05-09),

Title: The Innovative Journey of Seetharamaiyer Padmanabhan

Introduction: Seetharamaiyer Padmanabhan is a prolific inventor based in Lexington, MA, known for his groundbreaking contributions in the field of pharmaceutical sciences. With an impressive portfolio of 15 patents, Padmanabhan has made significant strides in the development of compounds and methods aimed at treating various diseases.

Latest Patents: Among his latest patents, Padmanabhan has disclosed novel compounds and compositions that activate or induce the expression of pattern recognition receptors such as STING, RIG-I, and MDA5. These innovations are crucial for advancing therapeutic strategies for disease treatment, showcasing his expertise and commitment to medical advancements.

Career Highlights: Padmanabhan has had a remarkable career in the pharmaceutical industry, with associations with notable companies such as Spring Bank Pharmaceuticals, Inc. and F-star Therapeutics, Inc. His work has been pivotal in advancing the understanding and capabilities of therapeutic agents, contributing to innovations that have the potential to change patients' lives.

Collaborations: Throughout his career, Padmanabhan has collaborated with talented individuals including Radhakrishnan P Iyer and Anjaneyulu Sheri. These partnerships reflect a collective effort in research and development, enhancing the innovation landscape within the pharmaceutical domain.

Conclusion: Seetharamaiyer Padmanabhan exemplifies the spirit of innovation, with his numerous patents and collaborations marking him as a key figure in the pursuit of medical breakthroughs. His ongoing contributions not only enrich the scientific community but also hold promise for more effective treatment methodologies in the future.

Profile summary based on public USPTO records.